“I have one big concern and that’s the garbage in, garbage out issue in the sense that these models are trained on available evidence.” – European Medicines Agency's Steffen Thirstrup on a potential limitation involved with using AI in the assessment of drug applications. Find out more: EMA, US FDA Worry About AIs Pitfalls And Promises
“When you move into the zone of results with a missed primary endpoint, that is when the differences between regulators become more pronounced… In Europe you may have more of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?